There is genuine excitement within the gynecologic cancer clinical and research communities for the potential role of PARP inhibitors in the management of ovarian cancer.
2017 August
About 71% of patients (17 of 24) with chronic lymphocytic leukemia exhibited an overall response (complete and/ or partial response) 4 weeks after receiving CAR T cell infusion therapy.
Savolitinib, Small-Molecule MET Kinase Inhibitor, Demonstrates Safety and Efficacy in Phase II Study
Patients with metastatic papillary renal cell carcinoma have limited therapeutic options, but results of a phase II safety and efficacy study suggest that a small-molecule inhibitor, savolitinib, could help patients with MET-driven disease.
The investigators discuss their findings that demonstrate patients with previous radiotherapy experienced significantly longer PFS and OS with pembrolizumab treatment versus those with no previous radiotherapy.
The authors share their experience with EGFRvIII-specific chimeric antigen receptors, which they hope will contribute to the growing body of research committed to discovering a novel therapy for glioblastoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
